Trials / Completed
CompletedNCT04143815
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
PhaseII, Randomized, Double-blind, Placebo Controlled, Multi-center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBA-P01 (Botulinum toxin A) | Intramuscular injection, dose varies by groups |
| DRUG | Placebo | Intramuscular injection |
Timeline
- Start date
- 2019-05-20
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2019-10-29
- Last updated
- 2021-03-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04143815. Inclusion in this directory is not an endorsement.